Compare iShares MSCI Germany (DAX) (EWG) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs Incyte Corporation — how do they compare? iShares MSCI Germany (DAX) trades at $43.83, while Incyte Corporation trades at $121.06 (market cap $24.54B). Which is the better fit depends on your goals.
| EWG | INCY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $44.56 | $129.93 |
52-Week Low | $38.08 | $81.61 |
Market Cap | — | $24.54B |
Enterprise Value | — | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG trades at $43.815, down slightly by 0.13% on the day, with a bullish technical signal driven by moving averages but neutral oscillators. The stock lacks available fundamental data for valuation and profitability metrics. Recent news highlights European Central Bank policy and German economic developments influencing regional market sentiment.
The outlook remains tied to European economic trends and monetary policy. Risks include energy price volatility and geopolitical tensions, while opportunities may arise from German fiscal support and market rotations into European equities. Investors should assess fundamental data when available for a complete view.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
